Article

Molecular tumor profile: another consideration for postmastectomy radiotherapy


 

I enjoyed the review article by Dr. Jeannie Shen (Community Oncology, December 2010), both for her succinct summary of the indications for postmastectomy plastic surgical reconstruction and the optimal timing of the procedure. Her salient presentation contained some of the most contemporary indications for postmastectomy radiotherapy (PMRT).

Along with the points Dr. Shen mentioned as indicators for PMRT— tumor size, regional nodal involvement, presence of lymphovascular space invasion, and patient youth—I would add estrogen receptor-negative disease as another tumor factor to consider for adjuvant radiotherapy. Many series, including some of those referenced by Dr. Shen and the American Society of Clinical Oncology in the composition of its recommendations, have demonstrated that estrogen receptor-negative status represents an independent risk factor for locoregionally recurrent disease after mastectomy and that the risk is significantly reduced by PMRT.1–7 ...

* For a PDF of the full article, click in the link to the left of this introduction.

Recommended Reading

Occult Sentinel Node Metastases Don't Impact Survival
Breast Cancer ICYMI
Cutting Through the Noise on Avastin
Breast Cancer ICYMI
Avastin Anon and On and On
Breast Cancer ICYMI
Point/Counterpoint: Does Surgery Improve Survival in Stage IV Breast Cancer?
Breast Cancer ICYMI
CAD Software Does Not Improve Mammogram Accuracy
Breast Cancer ICYMI
Dual HER2 Blockade Strategies Advance in Breast Cancer Trials
Breast Cancer ICYMI
Uncertainty Rules Adjuvant Chemo for Early HER2 Breast Cancer
Breast Cancer ICYMI
U.K. Committee Calls Fulvestrant Unwise Use of Resources
Breast Cancer ICYMI
Understanding the estrogen receptor signaling PATHWAY: focus on current endocrine agents for breast cancer in postmenopausal women
Breast Cancer ICYMI
Community Oncology Podcast - Exemestane for preventing breast cancer
Breast Cancer ICYMI